Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Trickle Portfolio -- Ignore unavailable to you. Want to Upgrade?

To: jsabelko who wrote (1040)	2/4/2002 1:11:44 AM
From: tuck	Read Replies (1) \| Respond to of 1784

joby, Fundamentally, I like CRS, mainly for the reasons you list. The sell was more of a portfolio management and trading decision. The Lab Automation show may have goosed it in the same way ASCO pops some therapeutic companies; problem is, they tend to sell off a bit afterwards these days. RSI and stochs are short term overbought, and $3.5 seems to be a resistance point. finance.yahoo.com And finally, Trickle was happy to be able to book a profit on something; it's had a rough life. Should CRS retreat back under $3, and I have cash that I have no better use for, I may well buy in again. I may never get that chance, for the long term looks good for CRS. In short, no reason to follow in my footsteps on this trade. Cheers, Tuck